While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Earnings Call Transcript January 30, 2025 Sanofi misses on earnings expectations. Reported EPS is $0.7 EPS, expectations were ...

In addition, we refer you to our Form 20-F on ... I'll first start off by reiterating what Paul said in his opening remarks. We couldn't be more pleased with Dupixent's full year performance ...

We are off to a promising start in COPD following approvals in more than 30 countries. In the U.S., the FDA approved Dupixent in September of last year, and we are very encouraged by our progress ...

Sanofi’s new atopic dermatitis treatment Dupixent has gained EU approval ... The drug has got off to a flying start in the US market, achieving rapid uptake since its launch in April, despite ...

That gives it an advantage over other biologics for severe asthma, such as Sanofi/Regeneron's IL-4/IL-13 inhibitor Dupixent (dupilumab ... AZ's partner Amgen since the start of 2022.

BCMAxCD3/Dupixent in severe allergy ... hemoglobinuria (Phase 3 registrational data expected in 2026+) and geographic atrophy, an advanced form of dry AMD (Phase 3 pivotal program underway). DNA ...

Students who have accepted their offer of admission for Fall 2025 may request to switch to Early Start by submitting the “Early Start” form under the Reply Forms tab in their admissions application ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Below is a list of the most common questions we receive in our office. If you do not see your question, please feel free to visit our Contact Page and reach out directly. Purdue Early Start is an ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...